MedTrace Logo

MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease

NCT04121208 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2024-05-09

No results posted yet for this study

Summary

A phase 1 randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive impairment. A maximum of 54 participants will be recruited to the two part study. The first part of the study will identify whether it is possible to identify biomarkers that may be used in future studies with JNJ-40346527 and part 2 will investigate a minimal efficacious JNJ-40346527 dose.

Conditions

Interventions

DRUG

JNJ-40346527

Active study drug

OTHER

Placebo

Non-active study drug

Sponsors & Collaborators

  • Janssen Pharmaceutica

    collaborator INDUSTRY

  • University of Oxford

    lead OTHER

Principal Investigators

  • Vanessa Raymont · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-07
Primary Completion
2022-02-18
Completion
2022-02-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04121208 on ClinicalTrials.gov